---
title: "BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295220567.md"
description: "BioVie released a corporate presentation detailing its neurodegeneration and liver disease programs. Key highlights include bezisterim, an oral TNFα modulator for Parkinson’s, Long COVID, and Alzheimer’s, with topline Phase 2b/2 data expected in 3Q 2026 showing reduced worsening versus placebo. Additionally, BIV201, a continuous IV terlipressin formulation for ascites, is described as Phase 3-ready with FDA-agreed design and Fast Track status. The company cited significant US sales potential across these indications."
datetime: "2026-08-07T10:39:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295220567.md)
  - [en](https://longbridge.com/en/news/295220567.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295220567.md)
generator: "portal-rs"
---

# BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease

-   BioVie highlighted bezisterim, an oral small molecule designed to modulate TNFα-driven inflammation across Parkinson’s disease, Long COVID, and Alzheimer’s disease. \* Topline data expected in 3Q 2026 for SUNRISE-PD Phase 2b in Parkinson’s disease; ADDRESS-LC Phase 2 in Long COVID. \* Bezisterim showed a smaller mean worsening than placebo on MDS-UPDRS Part I-III and total in an ITT set of 57 patients. \* BIV201, a continuous IV terlipressin formulation for ascites, described as Phase 3-ready with an FDA-agreed design, Fast Track, Orphan status. \* Pipeline materials cited US annual sales potential of $3 billion for Parkinson’s, $10 billion for Long COVID, $30 billion for Alzheimer’s, $1.6 billion for ascites. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md)
- [BIVIW.US](https://longbridge.com/en/quote/BIVIW.US.md)

## Related News & Research

- [BIVI: Bezisterim showed significant clinical and biomarker benefits in early Parkinson's, supporting Phase 3](https://longbridge.com/en/news/295701512.md)
- [BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegeneration](https://longbridge.com/en/news/295718009.md)
- [BioVie posts corporate presentation outlining bezisterim and BIV201 clinical programs](https://longbridge.com/en/news/295103451.md)
- [Rhelion signs supply license with Toronto’s UHN for psilocybin trial in Parkinson’s depression](https://longbridge.com/en/news/296134949.md)
- [BioVie says Phase 2 SUNRISE-PD trial shows bezisterim improves motor and non-motor symptoms in early Parkinson’s disease](https://longbridge.com/en/news/295101020.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**